viewDechra Pharmaceutical

Dechra Pharma still working to fix supply problems

The veterinary pharmaceuticals group said “many” of the supply issues had been mitigated

Dechra Pharmaceutical - Dechra Pharma still working to fix supply problems

Dechra Pharmaceuticals PLC (LON:DPH) said it “remains confident” about prospects for the current financial year.

Last month in its full-year results the veterinary pharmaceuticals group said it had faced supply chain issues at some of its sites and with contract manufacturers.

In a statement ahead of its annual shareholder meeting on Friday, the FTSE 250 company said it was continuing to resolve these issues but assured that “many of these now been mitigated”.

In preparation for Brexit, Dechra has been changing the ownership of all UK marketing authorisations to the Netherlands, while moving lab testing to Croatia and increasing inventories to avoid potential port delays.

The next scheduled news from Dechra will be its interims in late February.

Quick facts: Dechra Pharmaceutical

Price: 2746 GBX

Market: LSE
Market Cap: £2.83 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Second coronavirus wave inevitable believes BB Healthcare Trust PLC's Paul Major

BB Healthcare Trust’s (LON:BBH) Paul Major believes a second wave of coronavirus infections is inevitable and he is positioning the trust’s portfolio accordingly. The view that it is sunny uplands for equity markets from here is slightly disconcerting, he told Proactive, even with the recent...

14 hours, 25 minutes ago

2 min read